Posadzki PP, Bajpai R, Kyaw BM, Roberts NJ, Brzezinski A, Christopoulos GI, et al
Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout
Coverage is expanding beyond Ontario, BC, and Alberta over the course of 2026, with pricing expected to mirror the US Hims & Hers structure
doi:10.1210/en.2010-0289 43
This article explains GLP-1 dosing, how to administer your injection correctly, and when dose adjustments occur, helping you follow your treatment plan safely whilst achieving optimal glycaemic control
25 A larger, double-blind RCT of 243 cancer patients receiving cisplatin or oxaliplatin and diagnosed with CIPN showed no significant difference in peripheral neuropathic symptoms between oral ALA 600 mg/day orally and placebo but further studies are needed to conclusively determine if ALA could benefit this subset of patients